Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;9(6):376-9.
doi: 10.1080/19336950.2015.1081725. Epub 2015 Nov 10.

Validation of ion channel targets

Aaron C Gerlach  1 , Brett M Antonio  1
Affiliations
Review

Validation of ion channel targets

Aaron C Gerlach et al. Channels (Austin). 2015.

Abstract

A prerequisite for a successful target-based drug discovery program is a robust data set that increases confidence in the validation of the molecular target and the therapeutic approach. Given the significant time and resource investment required to carry a drug to market, early selection of targets that can be modulated safely and effectively forms the basis for a strong portfolio and pipeline. In this article we present some of the more useful scientific approaches that can be applied toward the validation of ion channel targets, a molecular family with a history of clinical success in therapeutic areas such as cardiovascular, respiratory, pain and neuroscience.

Keywords: drug discovery; ion channel; modulator; proof of mechanism; validation.

PubMed Disclaimer

References

    1. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK. A potassium channel mutation in neonatal human epilepsy. Science (New York, N.Y.) 1998; 279(5349):403-6; PMID:; http://dx.doi.org/10.1126/science.279.5349.403 - DOI - PubMed
    1. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, et al.. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18(1):25-9; PMID:; http://dx.doi.org/10.1038/ng0198-25 - DOI - PubMed
    1. Porter RJ, Burdette DE, Gil-Nagel A, Hall ST, White R, Shaikh S, DeRossett SE. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. Epilepsy Res 2012; 101(1-2):103-12; PMID:; http://dx.doi.org/10.1016/j.eplepsyres.2012.03.010 - DOI - PubMed
    1. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin N Am 2000; 84(3):597-607; PMID:; http://dx.doi.org/10.1016/S0025-7125(05)70243-1 - DOI - PubMed
    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med 2011; 365(18):1663-72; PMID:; http://dx.doi.org/10.1056/NEJMoa1105185 - DOI - PMC - PubMed

LinkOut - more resources